E1 ReplicatedPreliminaryPEM unclearRCTPeer-reviewedMachine draft
Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up.
Lerner, A Martin, Beqaj, Safedin H, Deeter, Robert G et al. · In vivo (Athens, Greece) · 2007
Quick Summary
This study tested whether the antiviral drug valacyclovir could help ME/CFS patients who had evidence of active Epstein-Barr virus (EBV) infection. Patients taking valacyclovir showed slightly larger improvements in physical energy and activity levels compared to those taking placebo over 6 months, and these gains continued over 3 years of follow-up. Heart rhythm problems also improved, and markers of active EBV infection decreased in the blood.
Why It Matters
This study provides preliminary evidence that active EBV replication may contribute to ME/CFS symptoms in a subset of patients and that antiviral treatment targeting this subset could produce measurable improvements in physical function and cardiac parameters. If validated in larger trials, this could support the development of a mechanistic subtype classification for ME/CFS and personalized treatment strategies.
Observed Findings
- Valacyclovir-treated patients experienced a mean Energy Index increase of +1.12 units (122 kcal/day) versus +0.42 units (65 kcal/day) in the placebo group at 6 months.
- Energy Index scores continued to increase progressively in the 36-month follow-up cohort.
- Sinus tachycardia decreased and abnormal cardiac wall motion improved over the study period.
- Serum EBV viral capsid antigen (VCA) IgM antibody titers decreased during treatment.
- Patients reported resumption of normal activities.
Inferred Conclusions
- The authors suggest that EBV replication is present in a clinically meaningful subset of ME/CFS patients and that subset classification is necessary for CFS research and treatment.
- Valacyclovir may produce modest but sustained improvements in physical capacity and cardiac function in EBV-positive ME/CFS patients.
- Reduction in EBV serology markers correlates with symptomatic improvement, suggesting viral reactivation contributes to disease in this subset.
Remaining Questions
- What proportion of the overall ME/CFS population meets criteria for the EBV-positive subset, and how should patients be selected for EBV serology-based classification?
- What is the optimal dose, duration, and long-term safety profile of valacyclovir in this population, and does benefit persist after treatment cessation?
What This Study Does Not Prove
This study does not prove that EBV causes ME/CFS in all patients or that valacyclovir is effective as a general ME/CFS treatment—only in patients with serological evidence of active EBV infection. The small sample size and lack of reported statistical significance testing limit generalizability, and improvement does not establish causation; improvement could reflect natural recovery, placebo effects, or time-dependent factors rather than antiviral action alone.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Phenotype:Infection-Triggered
Method Flag:PEM Not DefinedWeak Case DefinitionSmall SampleExploratory Only
Metadata
- PMID
- 18019402
- Review status
- Machine draft
- Evidence level
- Replicated human evidence from multiple independent studies
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →